Infectious Complications Following Prostate Biopsy: A Single Institution Review

• Mark Ferretti

  Department of Urology, New York Medical College, NY, USA

• Akhil Saji

  Department of Urology, New York Medical College, NY, USA

• Roopali Mittal

  Health Science Center, Oklahoma State University, Oklahoma City, OK 73104, USA

• Amit K. Tiwari

  Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, OH, USA

Purpose: Determine incidence of fluoroquinolone-resistant bacteria complications among patients following prostate biopsy at New York Medical College, NY.Materials and Methods: Retrospective chart review of 229 consecutive patients receiving prostate biopsy between 2009 and 2013 at New York Medical College, NY. Each was administered a Fleet enema the morning of and a three-day course of ciprofloxacin starting the day before biopsy. Results: The 1.3% (3/229) of patients developed infectious complications following biopsy. Each of the (3/3) species isolated was fluoroquinolone-resistant. Among patients developing infectious complications, all had prior exposure to fluoroquinolones and all infectious complications were fluoroquinolone-resistant.Conclusion: This study highlights the need for confirming the patient’s exposure history with fluoroquinolones and considering another class of antibiotics for patients with prior fluoroquinolone exposure to avoid infectious complications following prostate biopsies.

• PDF